Polycystic ovary syndrome, hyperandrogenism, and insulin resistance.

[1]  B. Corenblum,et al.  Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. , 2000, The Journal of clinical endocrinology and metabolism.

[2]  P. McKeigue,et al.  Cardiovascular disease in women with polycystic ovary syndrome at long‐term follow‐up: a retrospective cohort study , 2000, Clinical endocrinology.

[3]  Kristina Schoonjans,et al.  Thiazolidinediones: an update , 2000, The Lancet.

[4]  T. Davern,et al.  Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group. , 2000, Digestive diseases and sciences.

[5]  G. Lewis,et al.  Correction of hyperandrogenemia by laparoscopic ovarian cautery in women with polycystic ovarian syndrome is not accompanied by improved insulin sensitivity or lipid-lipoprotein levels. , 1999, The Journal of clinical endocrinology and metabolism.

[6]  G A Colditz,et al.  Guidelines for healthy weight. , 1999, The New England journal of medicine.

[7]  B. Kahn,et al.  Glucose transporters and insulin action--implications for insulin resistance and diabetes mellitus. , 1999, The New England journal of medicine.

[8]  Z Trajanoski,et al.  Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. , 1999, The New England journal of medicine.

[9]  D. Jakubowicz,et al.  Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome , 1999 .

[10]  A. Pfeiffer,et al.  Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. , 1998, The New England journal of medicine.

[11]  J. Olefsky,et al.  Lack of insulin resistance in fibroblasts from subjects with polycystic ovary syndrome. , 1998, Metabolism: clinical and experimental.

[12]  E. Ferrannini.  Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. , 1998, Endocrine reviews.

[13]  K. Siddle,et al.  Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. , 1998, The Biochemical journal.

[14]  B. Neuschwander‐Tetri,et al.  Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report , 1998, Annals of Internal Medicine.

[15]  S. Wild,et al.  Mortality of women with polycystic ovary syndrome at long-term follow-up. , 1998, Journal of clinical epidemiology.

[16]  M. McCarthy,et al.  Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome , 1997, The Lancet.

[17]  R. DeFronzo.  PATHOGENESIS OF TYPE 2 DIABETES: METABOLIC AND MOLECULAR IMPLICATIONS FOR IDENTIFYING DIABETES GENES , 1997 .

[18]  J. Olefsky,et al.  Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes , 1996, Diabetes.

[19]  B. Spiegelman,et al.  Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha. , 1996, Molecular endocrinology.

[20]  E. Van Obberghen,et al.  Overexpression of a Constitutively Active Form of Phosphatidylinositol 3-Kinase Is Sufficient to Promote Glut 4 Translocation in Adipocytes* , 1996, The Journal of Biological Chemistry.

[21]  D. Finegood,et al.  The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. , 1996, The Journal of clinical endocrinology and metabolism.

[22]  S. O’Rahilly,et al.  Molecular scanning of the insulin receptor gene in women with polycystic ovarian syndrome. , 1996, The Journal of clinical endocrinology and metabolism.

[23]  W. Miller,et al.  Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. Dunaif,et al.  Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. , 1995, The Journal of clinical investigation.

[25]  L. Kuller,et al.  Coronary heart disease risk factors in women with polycystic ovary syndrome. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[26]  D. Ehrmann,et al.  Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. , 1995, Endocrine reviews.

[27]  C. Deal,et al.  Regulation of extragonadal insulin-like growth factor-binding protein-3 by testosterone in oophorectomized women. , 1994, The Journal of clinical endocrinology and metabolism.

[28]  B. Spiegelman,et al.  Tumor Necrosis Factor α: A Key Component of the Obesity-Diabetes Link , 1994, Diabetes.

[29]  C. R. Kahn,et al.  Insulin Action, Diabetogenes, and the Cause of Type II Diabetes , 1994, Diabetes.

[30]  R. Barbieri.  Hyperandrogenism, insulin resistance and acanthosis nigricans. 10 years of progress. , 1994, The Journal of reproductive medicine.

[31]  R. Legro,et al.  Polycystic ovary syndrome. , 1992, Current therapy in endocrinology and metabolism.

[32]  L. Phillips,et al.  Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding protein 1 gene transcription by hormones and provision of amino acids in rat hepatocytes. , 1993, Molecular Endocrinology.

[33]  K. Alberti,et al.  Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary syndrome. , 1993, The Journal of clinical endocrinology and metabolism.

[34]  F. Pi‐Sunyer,et al.  Medical Hazards of Obesity , 1993, Annals of Internal Medicine.

[35]  E. Renard,et al.  Body Composition and Regional Fat Distribution in Polycystic Ovarian Syndrome Relationship to Hormonal and Metabolic Profiles , 1993, Annals of the New York Academy of Sciences.

[36]  B. Hansen,et al.  Chiroinositol deficiency and insulin resistance. II. Acute effects of D-chiroinositol administration in streptozotocin-diabetic rats, normal rats given a glucose load, and spontaneously insulin-resistant rhesus monkeys. , 1993, Endocrinology.

[37]  D. Rosenbaum,et al.  Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes. , 1993, The American journal of physiology.

[38]  D. Finegood,et al.  Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. , 1992, The Journal of clinical endocrinology and metabolism.

[39]  C. Bailey.  Biguanides and NIDDM , 1992, Diabetes Care.

[40]  S. Johansson,et al.  Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. , 1992, Fertility and sterility.

[41]  R. DeFronzo,et al.  Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. , 1991, The Journal of clinical endocrinology and metabolism.

[42]  R. DeFronzo,et al.  Effect of acute physiological elevations of insulin on circulating androgen levels in nonobese women. , 1991, The Journal of clinical endocrinology and metabolism.

[43]  R. DeFronzo,et al.  Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease , 1991, Diabetes Care.

[44]  J. Clore,et al.  A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. , 1991, The Journal of clinical endocrinology and metabolism.

[45]  L. Poretsky,et al.  Persistent insulin resistance after normalization of androgen levels in a woman with congenital adrenal hyperplasia. A case report. , 1989, The Journal of reproductive medicine.

[46]  J. Clore,et al.  Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. , 1989, The Journal of clinical endocrinology and metabolism.

[47]  J. Cara,et al.  Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. , 1988, Endocrinology.

[48]  A. Dunaif,et al.  The effects of experimental hyperinsulinemia on steroid secretion, ovarian [125I]insulin binding, and ovarian [125I]insulin-like growth-factor I binding in the rat. , 1988, Endocrinology.

[49]  A. Dunaif,et al.  Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. , 1987, The Journal of clinical endocrinology and metabolism.

[50]  J. Clore,et al.  The effects of hyperinsulinemia on serum testosterone, progesterone, dehydroepiandrosterone sulfate, and cortisol levels in normal women and in a woman with hyperandrogenism, insulin resistance, and acanthosis nigricans. , 1987, The Journal of clinical endocrinology and metabolism.

[51]  N. Bersch,et al.  Persistence of insulin resistance in polycystic ovarian disease after inhibition of ovarian steroid secretion. , 1986, Fertility and sterility.

[52]  R. Lobo,et al.  Insulin resistance in polycystic ovary syndrome. , 1983, American journal of obstetrics and gynecology.

[53]  R. Barbieri,et al.  Effects of insulin on steroidogenesis in cultured porcine ovarian theca. , 1983, Fertility and sterility.

[54]  S. Kaplan,et al.  Insulin resistance in nonobese patients with polycystic ovarian disease. , 1983, The Journal of clinical endocrinology and metabolism.

[55]  C. Kahn,et al.  Insulin stimulates the phosphorylation of the 95,000-dalton subunit of its own receptor. , 1982, Science.

[56]  E. Adashi,et al.  Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. , 1981, Endocrinology.

[57]  A. Kitabchi,et al.  Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. , 1980, The Journal of clinical endocrinology and metabolism.

[58]  C. Kahn,et al.  The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. , 1976, The New England journal of medicine.